JW (Cayman) Therapeutics Co. Ltd. (HK:2126)
:2126
Want to see HK:2126 full AI Analyst Report?
Total Valuation
JW (Cayman) Therapeutics Co. Ltd. has a market cap or net worth of HK$858.46M. The enterprise value is HK$507.69M.
Market CapHK$858.46M
Enterprise ValueHK$507.69M
Share Statistics
JW (Cayman) Therapeutics Co. Ltd. has 416,729,430 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding416,729,430
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
JW (Cayman) Therapeutics Co. Ltd.’s return on equity (ROE) is -0.97 and return on invested capital (ROIC) is -29.51%.
Return on Equity (ROE)-0.97
Return on Assets (ROA)-0.55
Return on Invested Capital (ROIC)-29.51%
Return on Capital Employed (ROCE)-0.41
Revenue Per Employee983.32K
Profits Per Employee-1.98M
Employee Count281
Asset Turnover0.28
Inventory Turnover2.54
Valuation Ratios
The current PE Ratio of JW (Cayman) Therapeutics Co. Ltd. is ―. JW (Cayman) Therapeutics Co. Ltd.’s PEG ratio is 0.19.
PE Ratio―
PS Ratio3.39
PB Ratio1.68
Price to Fair Value1.68
Price to FCF-11.95
Price to Operating Cash Flow-9.72
PEG Ratio0.19
Income Statement
In the last 12 months, JW (Cayman) Therapeutics Co. Ltd. had revenue of 276.31M and earned -540.92M in profits. Earnings per share was -1.30.
Revenue276.31M
Gross Profit118.91M
Operating Income-241.71M
Pretax Income-537.93M
Net Income-540.92M
EBITDA-161.95M
Earnings Per Share (EPS)-1.30
Cash Flow
In the last 12 months, operating cash flow was -76.85M and capital expenditures -1.62M, giving a free cash flow of -78.46M billion.
Operating Cash Flow-76.85M
Free Cash Flow-78.46M
Free Cash Flow per Share-0.19
Dividends & Yields
JW (Cayman) Therapeutics Co. Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.80
52-Week Price Change21.05%
50-Day Moving Average2.20
200-Day Moving Average3.31
Relative Strength Index (RSI)37.72
Average Volume (3m)2.67M
Important Dates
JW (Cayman) Therapeutics Co. Ltd. upcoming earnings date is Sep 1, 2026, TBA (Confirmed).
Last Earnings DateMar 26, 2026
Next Earnings DateSep 1, 2026
Ex-Dividend Date―
Financial Position
JW (Cayman) Therapeutics Co. Ltd. as a current ratio of 1.45, with Debt / Equity ratio of 47.20%
Current Ratio1.45
Quick Ratio1.29
Debt to Market Cap0.25
Net Debt to EBITDA1.49
Interest Coverage Ratio-21.70
Taxes
In the past 12 months, JW (Cayman) Therapeutics Co. Ltd. has paid 2.99M in taxes.
Income Tax2.99M
Effective Tax Rate>-0.01
Enterprise Valuation
JW (Cayman) Therapeutics Co. Ltd. EV to EBITDA ratio is -4.30, with an EV/FCF ratio of -8.88.
EV to Sales2.52
EV to EBITDA-4.30
EV to Free Cash Flow-8.88
EV to Operating Cash Flow-9.07
Balance Sheet
JW (Cayman) Therapeutics Co. Ltd. has HK$503.28M in cash and marketable securities with HK$262.67M in debt, giving a net cash position of HK$240.61M billion.
Cash & Marketable SecuritiesHK$503.28M
Total DebtHK$262.67M
Net CashHK$240.61M
Net Cash Per ShareHK$0.58
Tangible Book Value Per ShareHK$0.86
Margins
Gross margin is 43.15%, with operating margin of -87.48%, and net profit margin of -195.76%.
Gross Margin43.15%
Operating Margin-87.48%
Pretax Margin-194.68%
Net Profit Margin-195.76%
EBITDA Margin-58.61%
EBIT Margin-87.48%
Analyst Forecast
The average price target for JW (Cayman) Therapeutics Co. Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast79.76%
EPS Growth Forecast7.68%